The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
PreviousPrevious
Volume 356:2674 June 28, 2007 Number 26
NextNext

First-Trimester SSRIs and the Risk of Birth Defects

Since this article has no abstract, we have provided an extract of the first 100% of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF

Commentary
-Editorial
by Greene, M. F.

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Louik, C.
In this large case–control study, the first-trimester use of selective serotonin-reuptake inhibitors (SSRIs) overall was not associated with significantly increased risks of craniosynostosis, omphalocele, or heart defects. Analyses of individual SSRIs revealed some significant associations; however, the analyses involved multiple comparisons and small numbers of exposed subjects. These findings do not show significantly increased risks of major birth defects in association with SSRI use overall.



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.